INTERMEDIATE RISK CHRONIC LYMPHOCYTIC LEUKEMIA

Clinical trials for INTERMEDIATE RISK CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.

Never miss a new study

Get alerted when new INTERMEDIATE RISK CHRONIC LYMPHOCYTIC LEUKEMIA trials appear

Sign up with your email to follow new studies for INTERMEDIATE RISK CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New drug combo challenges chemo for leukemia treatment

Disease control Completed

This study tested whether a newer, chemotherapy-free combination of two targeted drugs (venetoclax and ibrutinib) could be as good as or better than the standard chemotherapy-based treatment (FCR) for patients with intermediate-risk chronic lymphocytic leukemia (CLL). It involved…

Matched conditions: INTERMEDIATE RISK CHRONIC LYMPHOCYTIC LEUKEMIA

Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

INTERMEDIATE RISK CHRONIC LYMPHOCYTIC LEUKEMIA

Get alerted when new INTERMEDIATE RISK CHRONIC LYMPHOCYTIC LEUKEMIA trials appear

New drug combo challenges chemo for leukemia treatment